Targeted Medical Pharma Osake

Targeted Medical Pharma PEG

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Targeted Medical Pharma (TRGM) 17.8.2026 päivämäärällä on −0,00. Edellisenä vuonna PEG-suhde (Hinta-tuotto-kasvu-suhde) oli −0,00 — muutos 2 822,39 % (matalampi).

PEG

−0,00

YoY

2 822,39%

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Targeted Medical Pharma on 2026 −0,00 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Targeted Medical Pharma oli 2025 −0,00 . Se laskee 2 822,39% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Targeted Medical Pharma Osakeanalyysi

Mitä Targeted Medical Pharma tekee? Targeted Medical Pharma Inc is a California-based biotechnology company that focuses on the development and marketing of patented pharmaceutical products in the field of neuroscience and pulmonology. The company was founded in 1999 and has since placed emphasis on the development of patented pharmaceutical products that can be used in various medical areas. The main business model of Targeted Medical Pharma is to bring innovative product developments to the market that can bridge the gap between conventional medicine and integrative medicine. The company aims to create therapy options that are very specific to certain diseases, which can then be patented and marketed. However, disposable drugs (medicines that need to be administered once a year and then have long-term effects), as one knows from other companies, are not used. The company offers a wide range of different divisions and products that have been developed over the years. The main divisions covered by Targeted Medical Pharma include: 1. Neurology: Here, the company develops products for the treatment of neurological disorders such as ADHD, Alzheimer's, autism, depression, stroke, and other diseases of the central nervous system. 2. Pain management: In this division, Targeted Medical Pharma focuses on the development of products against chronic pain, back pain, and migraines. 3. Sports medicine: The goal of this division is to help athletes improve their performance and recovery and to prevent injuries. 4. Pulmonology: Here, Targeted Medical Pharma offers products targeting the treatment of lung problems such as asthma and COPD. Some of the well-known products developed by Targeted Medical Pharma include: 1. Sentra AM: A dietary supplement specifically developed to support the nervous system and used for the treatment of depression, anxiety, and other neurological disorders. 2. Theramine: A patented amino acid mixture developed for chronic pain, supporting the body in pain relief and fighting inflammation. 3. Aeropur: An inhalation device specifically developed for the treatment of asthma and COPD. 4. Clearwayz: A solution that helps loosen mucus and clear airways during colds and bronchitis. 5. Trepadone: A dietary supplement developed in collaboration with the US Navy to reduce inflammation and muscle soreness after intense physical training and improve recovery. The company has earned great respect in the industry and among investors, particularly through the continuous development of new products and emphasis on scientific research and clinical evidence. A seven-figure number of patients can benefit from these innovations. Targeted Medical Pharma has worked on the development of more than 25 different patented pharmaceutical products, several of which have already been approved by the FDA (Food and Drug Administration). The company has also established numerous valuable connections with academic institutions and healthcare facilities, which is expected to benefit the development of new and innovative products. Overall, Targeted Medical Pharma is a company specializing in patented product development. In fact, it is working hard to revolutionize the complementary medicine field by creating innovative therapies and treatments to have a lasting positive impact on the health and well-being of millions of people worldwide. Targeted Medical Pharma on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Targeted Medical Pharma osakkeesta

Yhtiön Targeted Medical Pharma PEG-suhde (Hinta-tuotto-kasvu-suhde) on −0,00 vuonna 2026.

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Targeted Medical Pharma muuttui arvosta −0,00 arvoon −0,00, mikä edustaa 2 822,39 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Targeted Medical Pharma:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Targeted Medical Pharma alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Targeted Medical Pharma

Kaikki tunnusluvut — Targeted Medical Pharma